Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis  Kenneth B. Gordon, Richard G. Langley,

Published byAndreja Mijatović Modified over 6 years ago

Similar presentations

Presentation on theme: "A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis  Kenneth B. Gordon, Richard G. Langley,"— Presentation transcript:

1 A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis  Kenneth B. Gordon, Richard G. Langley, Alice B. Gottlieb, Kim A. Papp, Gerald G. Krueger, Bruce E. Strober, David A. Williams, Yihua Gu, Joaquin M. Valdes  Journal of Investigative Dermatology  Volume 132, Issue 2, Pages (February 2012) DOI: /jid Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions

2 Figure 1 Study flow and patient disposition.1Lack of efficacy was defined as physician's global assessment (PGA) score of “mild” or higher. 2Lack of efficacy was defined as a PGA score of “moderate” or higher. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions

3 Figure 2 Proportions achieving physician's global assessment (PGA) “clear” or “minimal” or psoriasis area and severity index (PASI) 75 by treatment group during the induction phase. Intention-to-treat analysis: patients with missing scores were considered nonresponders. ***P<0.001 briakinumab versus placebo. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions

4 Figure 3 Maintenance-phase efficacy results. Maintenance of (a) physician's global assessment (PGA) “clear” or “minimal” and proportions achieving (b) psoriasis area and severity index (PASI) 75 and (c) PASI 100 through week 52. 1One patient in the briakinumab every-4-week group was re-randomized but did not receive any study drug in the maintenance phase. 2Represents all patients who received briakinumab in the induction phase, had a PGA score of “clear” or “minimal” at week 12, and were re-randomized in the maintenance phase. Intention-to-treat analysis: patients with missing scores were considered nonresponders. *P<0.05, **P<0.01, and ***P<0.001 briakinumab every 4 weeks and every 12 weeks versus placebo; for briakinumab every 4 weeks versus every 12 weeks, P<0.001 for all endpoints from weeks 20 to 52, and P<0.01 for PASI 75 at week 16. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions

Download ppt "A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis  Kenneth B. Gordon, Richard G. Langley,"

Similar presentations

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis  Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu,

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis  Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu,
Francesca Capon  Journal of Investigative Dermatology 

Francesca Capon  Journal of Investigative Dermatology 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
The Effect of a Connexin43-Based Peptide on the Healing of Chronic Venous Leg Ulcers: A Multicenter, Randomized Trial  Gautam S. Ghatnekar, Christina.

The Effect of a Connexin43-Based Peptide on the Healing of Chronic Venous Leg Ulcers: A Multicenter, Randomized Trial  Gautam S. Ghatnekar, Christina.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis  Alice B. Gottlieb, MD, PhD,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis  Alice B. Gottlieb, MD, PhD,
Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M
Comparative Effectiveness Research

Comparative Effectiveness Research
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.
A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis  Catharine.

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis  Catharine.
Clinical Snippets Journal of Investigative Dermatology

Clinical Snippets Journal of Investigative Dermatology
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.
Devita Surjana, Gary M. Halliday, Andrew J. Martin, Fergal J

Devita Surjana, Gary M. Halliday, Andrew J. Martin, Fergal J
Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis  Alexander Nast, Anja Jacobs,

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis  Alexander Nast, Anja Jacobs,
Databases for Clinical Research

Databases for Clinical Research
Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized,

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized,

Similar presentations

Ads by Google